Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients .
- Conditions
- Liver Cancer
- Interventions
- Drug: radiotherapy combined with Camrelizumab and Apatinib
- Registration Number
- NCT06632522
- Lead Sponsor
- Beijing Tsinghua Chang Gung Hospital
- Brief Summary
Clinical study of radiotherapy combined with Camrelizumab and Apatinib in the treatment of liver cancer patients with VP4.
- Detailed Description
This study is a single-arm, open, prospective and multi-center clinical study, aiming at observing and evaluating the efficacy and safety of radiotherapy combined with Camrelizumab and apatinib in the treatment of patients with VP4 liver cancer.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 46
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description radiotherapy combined with Camrelizumab and Apatinib radiotherapy combined with Camrelizumab and Apatinib radiotherapy combined with Camrelizumab and Apatinib in the treatment of liver cancer patients with VP4
- Primary Outcome Measures
Name Time Method Overall survival up to 3 years The time from the beginning of treatment to the progression of the disease or death from any cause.
- Secondary Outcome Measures
Name Time Method Progression-free survival up to 3 years Time elapsed from treatment to death from any cause
Objective response rate up to 3 years The proportion of patients with a confirmed complete response or partial response
Disease control rate up to 3 years The proportion of patients who have achieved complete remission (CR), partial remission (PR) or disease stability (SD) at least once after receiving the treatment of this research scheme.
Trial Locations
- Locations (1)
Beijing Tsinghua Chang Gung Hospital
🇨🇳Beijing, Beijing, China